Overview

Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacokinetics, safety and tolerability of aliskiren in healthy subjects and patients with End Stage Renal Disease on hemodialysis.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis